¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧ1998ÄêÃâÒßѧ£¨²©Ê¿£©
¼¶±ð: ²©Ê¿
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-20   

µÚËľüÒ½´óѧ1998ÄêÃâÒßѧ£¨²©Ê¿£©

µÚËľüÒ½´óѧ1998ÄêÃâÒßѧ£¨²©Ê¿£© d.o FlT  
38i,\@p`9$  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© 1s[-2^D+EM  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© :G/]rDtd  
1.Co-stimulators (or co-stimulating molecules) ! -@!u   
2.NK-kB P@`"MNS  
3.Immunoglobulin superfamily =A 6O}0z  
4.antigen-presenting cell (APC) olh3 R.M<  
5.death domain m]q!y3  
6.CCR and CXCR ; @~*z4U  
7.Lectin (or mitogen) T?{9Z  
8.Clusters of differentiation, CD) 5>Yd\(`K  
9.B7 family m-92G8'  
10.Cytotoxic T lymphocyte, CTL) { BL1j  
11.IL-15 and IL-15 receptor (IL-15R) ~ O=|v/]  
12.MHC restriction fhx:EZ:~  
13.Affinity-chromatography })vr*[  
14.Cyctosprin A, CsA >ImM~SR)  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) ,GP4I3D  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© Al=? j#J6p  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 } _l -'t  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ e4%*I8 ^e  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢á¹¹¼°Æäʶ±?¿¹Ô­µÄÌØµã¡£ 9|A-oS  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© bRz^=  
ÃâÒßѧרҵ£º }Rxg E~ F  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ q,JA~GG  
Ïû»¯ÄÚ¿Æ£º G,|]a#w&v.  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ \(U"_NPp  
ѪҺ²¡Ñ§×¨Òµ£º 7h#faOP  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
4+6=? ÕýÈ·´ð°¸:10
°´"Ctrl+Enter"Ö±½ÓÌá½»